Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab + AMG 404 in Small Cell Lung Cancer
NCT04885998Phase 1Completed
- Sponsor
- Amgen
- Start
- Sep 2021
- Primary completion
- Jul 2023
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 6
01
Overview
Phase 1, open-label trial of tarlatamab in small cell lung cancer (SCLC) (2 arms), sponsored by Amgen. Primary endpoints: Dose-limiting Toxicity at 28 days and Treatment-emergent Adverse Events. Started Sep 2021; status: completed.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04885998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04885998.